Clinical & Experimental Metastasis

, Volume 10, Issue 6, pp 411–418 | Cite as

Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone

  • Paul J. Kostenuik
  • Gurmit Singh
  • Kaye L. Suyama
  • F. William Orr

To test the hypothesis that bone metastasis is related to the rate of bone remodeling, we have examined the effect of enhanced bone resorption on the growth of spontaneously metastatic Walker 256 (W256) cancer cells. Bone resorption was stimulated in male Fischer rats by injecting Rice H-500 Leydig tumor cells subcutaneously. The resorptive response of the skeleton was confirmed in a pilot study by evaluating parameters of bone morphometry after 4, 7 and 10 days of tumor burden. The distal femoral epiphyses had 35 ± 10% more osteoclast surface, 83 ± 11% less osteoblast surface, and 46 ± 5% less trabecular bone after 10 days of tumor burden, compared to non-tumor-bearing controls. To evaluate the effect of Leydig tumor-induced bone resorption on the growth response of W256 cells, 20 rats were injected intramuscularly with 2 × 107 W256 cells, and 20 rats were vehicle-injected. Two days later, 10 rats from each group were injected subcutaneously with Leydig tumor cells. Twelve days after W256/vehicle injection, rats were injected with [3H]thymidine, killed 2 h later, and their femurs, liver, lungs and kidneys were processed for histology. In rats injected with Leydig tumor cells only, enhanced bone resorption was confirmed by a 40 ± 4% increase in serum calcium concentration, a 48 ± 8% decrease in trabecular bone content, and a 72 ± 15% decrease in osteoblast surface, compared with non-tumor-bearing rats. Metastatic W256 cells adjacent to trabecular bone in Leydig tumor-bearing rats had a 56 ± 18% greater relative [3H]thymidine labeling index (TdR) than did W256 cells in the bones of non-Leydig tumor-bearing rats. The TdRs of W256 cells in the liver, lungs, and kidneys were not affected by Leydig tumor burden. In this model, enhanced bone resorption was associated with the selective growth promotion of metastatic W256 cells in bone, suggesting the existence of a bone-derived factor which is mitogenic to W256 cells.


bone metastasis growth hypercalcemia osteolysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Naito S, Giavazzi R and Fidler IJ, 1987, Correlation between the in vitro interaction of tumor cells with an organ environment and metastatic behavior in vivo. Invasion and Metastasis, 7, 16–29.Google Scholar
  2. 2.
    Sargent NSE, Oestreicher M, Haidvogl H, Madnick HM and Burger MM, 1988, Growth regulation of cancer metastases by their host organ. Proceedings of the National Academy of Sciences, U.S.A., 85, 7251–7255.Google Scholar
  3. 3.
    Nicolson GL and Dulski KM, 1986, Organ specificity of metastatic tumor colonization is related to organ-selective growth properties of malignant cells. International Journal of Cancer, 38, 289–294.Google Scholar
  4. 4.
    Nicolson GL, 1988, Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer and Metastasis Reviews, 7, 143–188.Google Scholar
  5. 5.
    Easty GC and Carter RL. Patterns and mechanisms of bone destruction by skeletal metastases. In: Symington T and Carter RL, eds. Oncology Supplement: Scientific Foundation of Oncology. London: William Heinemann Medical Books, 1980.Google Scholar
  6. 6.
    Percival RC, Yates AJP, Gray RES, Galloway J, Rogers K, Neal FE and Kanis JA, 1985, Mechanisms of malignant hypercalcemia in carcinoma of the breast. British Medical Journal, 291, 776–777.Google Scholar
  7. 7.
    Shim SS, 1968, Physiology of blood circulation of bone. Journal of Bone and Joint Surgery, 50A, 812–824.Google Scholar
  8. 8.
    Powell N, 1983, Metastatic carcinoma in association with Paget's disease of bone. British Journal of Radiology, 56, 582–585.Google Scholar
  9. 9.
    Agha FP, Norman A, Hirschl S and Klein R, 1976, Paget's disease. Coexistence with metastatic carcinoma. New York State Journal of Medicine, May, 734–735.Google Scholar
  10. 10.
    Simpkins H, Lehman JM, Mazurkiewicz JE and Davis BH, 1991, A morphological and phenotypical analysis of Walker 256 cells. Cancer Research, 51, 1334–1338.Google Scholar
  11. 11.
    Krempien B, Wingen F, Eichmann T, Muller M and Schmahl D, 1988, Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxyprophylidene-1, 1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology, 45, 41–46.Google Scholar
  12. 12.
    Scharla SH, Minne HW, Lempert UG, Krieg P, Rappel S, Maurer E, Grohe U and Ziegler R, 1991, Osteolytic activity of Walker carcinoma 256 is due to parathyroid hormone-related protein (PTHrP). Hormone Metabolism Research, 23, 66–69. Kostenuik PJ, Singh G, Suyama L and Orr FW, 1992. atA quantitative model for spontaneous bone metastasis: evidence for a mitogenic effect of bone on Walker 256 cancer cells. Clinical and Experimental Metastasis, 10, 403–410.Google Scholar
  13. 13.
    Millar-Book W, Orr FW and Singh G, 1990, In vitro effects of bone and platelet-derived transforming growth factor-β on the growth of Walker 256 carcinosarcoma cells. Clinical and Experimental Metastasis, 8, 503–510.Google Scholar
  14. 14.
    Orr FW, Millar-Book W and Singh G, 1990, Chemotactic activity of bone and platelet-derived transforming growth factor beta for bone-metastasizing rat Walker 256 carcinosarcoma cells. Invasion and Metastasis, 10, 241–252.Google Scholar
  15. 15.
    Tam CS, Heersche JNM, Santora A and Spieger AM, 1984, Skeletal response in rats following implantation of hypercalcemia-producing Leydig cell tumors. Metabolism, 33, 50–53.Google Scholar
  16. 16.
    Insogna KL, Stewart AF, Vignery AMC, Weir EC, Namnum PA, Baron RE, Kirkwood JM, Deftos LM and Broadus AE, 1984, Biochemical and histo morphometric characterization of a rat model for humoral hypercalcemia of malignancy. Endocrinology, 114, 888–896.Google Scholar
  17. 17.
    Sica DA, Marotdam RR, Aronow J and Mundy GR, 1983, The hypercalcemic rat Leydig cell tumor-A model of the humoral hypercalcemia of malignancy. Calcified Tissue International, 35, 287–293.Google Scholar
  18. 18.
    Mortodam RR, Thornton KS, Sica DA, D'Souza SM, Flora L and Mundy GR, 1983, The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcified Tissue International, 35, 512–519.Google Scholar
  19. 19.
    Berger ME, Golub MS, Sowers JR, Brickman AS, Nyby M, Troyer H, Rude RK, Singer FR, Horst R and Deftos LM, 1982, Hypercalcemia in association with a Leydig cell tumor in the rat: a model for tumor-induced hypercalcemia in man. Life Sciences, 30, 1509–1515.Google Scholar
  20. 20.
    Insogna KL, Weir EC, Wu TL, Stewart AF, Broadus AE, Burtis WJ and Centrella M, 1987, Co-purification of transforming growth factor β-like activity with PTH-like and bone-resorbing activities from a tumor associated with humoral hypercalcemia of malignancy. Endocrinology, 120, 2183–2185.Google Scholar
  21. 21.
    Henderson J, Bernier S, D'Amour P and Goltzman D, 1990, Effects of passive immunization against parathyroid hormone (PTH)-like peptide and PTH in hypercalcemic tumor-bearing rats and normocalcemic controls. Endocrinology, 127, 1310–1318.Google Scholar
  22. 22.
    Yates AJP, Gutierrez GE, Smolens P, Travis PS, Katz MS, Aufdemorte TB, Boyce BF, Hymer TK, Poser JW and Mundy GR, 1988, Effects of a syn thetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. Journal of Clinical Investigation, 81, 932–938.Google Scholar
  23. 23.
    Kitazawa R, Imai Y, Fukase M and Fujita T, 1991, Effects of continuous infusion of parathyroid hormone and parathyroid hormone-related peptide on rat bone in vivo: comparative study by histomorphometry. Bone and Mineral, 12, 157–166.Google Scholar
  24. 24.
    Rayner DC, Orr FW and Shiu RPC, 1985, Binding of formyl peptides to Walker 256 carcinosarcoma cells and the chemotactic response of these cells. Cancer Research, 45, 2288–2293.Google Scholar
  25. 25.
    Schenk RK. Principles of bone morphometry. In: Jaworski ZFG, ed. Proceedings of the First Workshop on Bone Morphometry. Ottawa: University of Ottawa Press, 1976.Google Scholar
  26. 26.
    Revell PA. Quantitative methods in bone biopsy examination. In: Revell PA, ed. Pathology of Bone. New York, NY: Springer Verlag, 1986.Google Scholar
  27. 27.
    Simpson-Herren L. Autoradiographic techniques for measurement of the labeling index. In: Gray JW, ed. Techniques in Cell Cycle Analysis. Clifton, New Jersey: Human Press, 1987.Google Scholar
  28. 28.
    Bessey OA, Lowry OH and Brock MJ, 1946, A method for the rapid determination of alkaline phosphatase with 5 cubic millimeters of serum. Journal of Biological Chemistry, 164, 321–329.Google Scholar
  29. 29.
    Andersch MA and Szczypinski AJ, 1947, Use of p-nitrophenol phosphate substrate in determination of serum acid phosphatase. American Journal of Clinical Pathology, 17, 571–574.Google Scholar
  30. 30.
    Finkelman RD, Linkhart TA, Mohan S, Lau WKH, Baylink DJ and Bell NH, 1991, Vitamin D deficiency causes a selective reduction in deposition of transforming growth factor β in rat bone: possible mechanism for impaired osteoinduction. Proceedings of the National Academy of Sciences, U.S.A., 88, 3657–3660.Google Scholar
  31. 31.
    Robey PG, Young MF, Flanders KC, Roche NS, Kondaiah P, Reddi AH, Termine JD, Sporn MB and Roberts AB, 1987, Osteoblasts synthesize and respond to transforming growth factor-type (TGF-β) in vitro. Journal of Cell Biology, 105, 457–463.Google Scholar
  32. 32.
    Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennet RC and Martin TJ, 1991, Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Research, 51, 3059–3061.Google Scholar

Copyright information

© Rapid Communications of Oxford Ltd 1992

Authors and Affiliations

  • Paul J. Kostenuik
    • 1
  • Gurmit Singh
    • 1
  • Kaye L. Suyama
    • 1
  • F. William Orr
    • 1
  1. 1.Department of Pathology, Oncology Research GroupMcMaster University, and Hamilton Regional Cancer CentreHamiltonCanada

Personalised recommendations